|
|||||
|
|
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study |
|
| Authors: | Jean-Luc Raoul Jean-Luc Van Laethem Marc Peeters Catherine Brezault Fares Husseini Laurent Cals Johannes Nippgen Anja-Helena Loos Philippe Rougier |
| Affiliation: | 1. Digestive Oncology Department, Centre E Marquis, 35062, Rennes cedex, France 2. Gastroenterology Department, H?pital Universitaire Erasme, Route de Lennik 808, B-1070, Brussels, Belgium 3. Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium 4. H?pital Cochin, Paris, France 5. H?pital Pasteur, 39 Ave de la Liberté, 68024, Colmar cedex, France 6. Oncology Service, H?pital Font Pré, BP1412, 83056, Toulon cedex, France 7. Merck KGaA, Darmstadt, Germany 8. H?pital Ambroise Paré, 9 Avenue Charles de Gaulle, 92100, Boulogne cedex, France |
| Abstract: | BackgroundThis study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |